TranScrip Partners, a U.K.-based CRO, has created a U.S. office. The U.S. branch of TranScrip Partners will be led by Glenn Tillotson, a pharmaceutical expert with 25 years' industry experience and a successful track record in drug development and life cycle management.
The expansion of TranScrip Partners to the U.S. follows the opening of offices in Australia late last year and marks an important milestone in the expansion of TranScrip Partners.
"Establishing TranScrip's presence in the U.S. will allow us to better support our clients and their global drug development programs and will add to the depth and breadth of our expertise in drug development and commercialization," said Dr. Flic Gabbay, managing partner of TranScrip Partners.
TranScrip Partners supports biopharmaceutical product development and life-cycle management across a client base of over 80 companies. It challenges the traditional CRO model by offering both top-level therapeutic expertise in overcoming the hurdles encountered from translational medicine to successful registration and market access and the staff to support the projects. Services offered by TranScrip Partners include development and market positioning strategies for early molecules as well as tailored support in drug development, medical affairs, pharmacovigilance, regulatory and medical writing during pre- and post-approval.